Everest Medicines Receives the NMPA Recommendation of Priority Review for Cefepime-Taniborbactam to Treat Complicated Urinary Tract Infections
Shots:
- The NMPA has recommended a Priority Review for cefepime-taniborbactam to treat cUTI, incl. pyelonephritis, and treatment of major infectious diseases and rare diseases
- In Aug 2023, the US FDA accepted the NDA for cefepime-taniborbactam and granted a Priority Review with an anticipated PDUFA date of Feb 2024. The NDA was based on the P-III study (CERTAIN-1) of cefepime-taniborbactam
- Cefepime-taniborbactam, an IV beta-lactam/beta-lactamase inhibitor antibiotic being developed by Venatorx for cUTI incl. pyelonephritis. Under an exclusive license agreement with Venatorx, Everest gets the rights to develop and commercialize cefepime-taniborbactam in Greater China, South Korea & some Southeast Asian countries
Ref: PR Newswire | Image: Everest Medicines
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
